DNA

23andMe Research Institute Names Brad Margus and Stephen Quake, D.Phil., to Board of Directors

PALO ALTO, Calif., Oct. 24, 2025 (GLOBE NEWSWIRE) -- 23andMe Research Institute, a nonprofit medical research organization, today announced two…

1 month ago

SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio

TEL AVIV, Israel, Oct. 24, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company…

1 month ago

Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production

MILAN, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading…

1 month ago

Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025

TORONTO and HOUSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF),…

1 month ago

Genomic Prediction Files Federal Lawsuit to Protect Trade Secrets and Intellectual Property and Enforce Its Rights

NEWARK, N.J., Oct. 23, 2025 /PRNewswire/ -- Genomic Prediction Inc. ("GP"), a leader in advanced genetic testing and reproductive genomics, announced…

1 month ago

Generation Lab Raises $11M Seed Round as SystemAge™ Becomes World’s Fastest-Growing Longevity Diagnostic

Among the top 1% of startup raises, the round will accelerate adoption of the SystemAge breakthrough aging diagnostic platform across…

1 month ago

Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer’s “Kill-and-Clean” Defense Systems in an Aggressive Prostate Cancer Model, Outperforming Rapamycin and Chemo

New findings highlight Telomir-1's impact on CASP8 and GSTP1, two critical genes that regulate cell death and glutathione-based detoxification pathways…

1 month ago

MAIA Biotechnology Details 30-Month Patient Survival in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer

Outstanding measure of efficacy relative to high-risk cancers with limited treatment options CHICAGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- MAIA…

1 month ago

MGI Tech partners with Eva Holding Group to enhance the accuracy of disease monitoring

SÃO PAULO, Oct. 22, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company dedicated to developing essential tools and technologies…

1 month ago